en
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Open in Telegram

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Show more

๐Ÿ“ˆ Analytical overview of Telegram channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Channel ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) in the Arabic language segment is an active participant. Currently, the community unites 13 291 subscribers, ranking 1 940 in the Medicine category and 5 731 in the Saudi Arabia region.

๐Ÿ“Š Audience metrics and dynamics

Since its creation on ะฝะตะฒั–ะดะพะผะพ, the project has demonstrated rapid growth, gathering an audience of 13 291 subscribers.

According to the latest data from 01 July, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 138 over the last 30 days and by -19 over the last 24 hours, overall reach remains high.

  • Verification status: Not verified
  • Engagement rate (ER): The average audience engagement rate is 29.30%. Within the first 24 hours after publication, content typically collects 10.12% reactions from the total number of subscribers.
  • Post reach: On average, each post receives 3 896 views. Within the first day, a publication typically gains 1 346 views.
  • Reactions and interaction: The audience actively supports content: the average number of reactions per post is 37.
  • Thematic interests: Content is focused on key topics such as ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ.

๐Ÿ“ Description and content policy

The author describes the resource as a platform for expressing subjective opinions:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Thanks to the high frequency of updates (latest data received on 02 July, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.

13 291
Subscribers
-1924 hours
-277 days
+13830 days
Posts Archive
Multidrug-Resistant ุญุฌูŠ ูƒุจูŠุฑ ุจุงู„ุนู…ุฑ ูŠุนุงู†ูŠ ู…ู† ุงู„ุชู‡ุงุจุงุช ููŠ ุงู„ู…ุณุงู„ูƒ ุงู„ุจูˆู„ูŠุฉ ู†ุชูŠุฌุฉ ุงู„ุตุฑู ุบูŠุฑ ุงู„ู…ุจุฑุฑ ูˆ ุงู„ุงุณุชุฎุฏุงู… ุงู„ุฎุงุทุฆ ู„ู„ู…ุถุงุฏุงุช ุง
Multidrug-Resistant ุญุฌูŠ ูƒุจูŠุฑ ุจุงู„ุนู…ุฑ ูŠุนุงู†ูŠ ู…ู† ุงู„ุชู‡ุงุจุงุช ููŠ ุงู„ู…ุณุงู„ูƒ ุงู„ุจูˆู„ูŠุฉ ู†ุชูŠุฌุฉ ุงู„ุตุฑู ุบูŠุฑ ุงู„ู…ุจุฑุฑ ูˆ ุงู„ุงุณุชุฎุฏุงู… ุงู„ุฎุงุทุฆ ู„ู„ู…ุถุงุฏุงุช ุงู„ุญูŠูˆูŠุฉ ู…ู† ู‚ุจู„ ู„ู„ู…ุฑูŠุถ ูƒุงุฑุซุฉ ูˆุงู„ู„ู‡ ุงู„ูˆุญูŠุฏ ุงู„ูŠ ู…ู…ูƒู† ูŠุณุชุฌูŠุจ ุงู„ู‡ ู‡ูˆ Tigecycline

ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุงุญู†ู‡ ุทู„ุงุจ ูƒู„ูŠุฉ ุงู„ุตูŠุฏู„ุฉ _ ุงู„ู…ุฑุญู„ู‡ ุงู„ุฎุงู…ุณู‡ ุนุฏู†ุง ุจุญุซ ุชุฎุฑุฌ ูˆู‡ุฐุง ุงุณุชุจูŠุงู† ูŠุฎุต ุงู„ุจุญุซ ุจู„ุง ุฒุญู…ู‡ ุนู„ูŠูƒู… ุชูƒุฏุฑูˆู† ุชุณุงุนุฏูˆู†ู‡ ุจุฏู‚ูŠู‚ู‡ ู…ู† ูˆู‚ุชูƒู… ูˆุชู…ู„ูˆู† ุงู„ุงุณุชุจูŠุงู† ู‡ุฐุง ูˆุดูƒุฑุงู‹ ู…ู‚ุฏู…ุงู‹ https://docs.google.com/forms/d/e/1FAIpQLScGe57JSan3P32y8GNr4iTXPoVm19cMV6_nE6f33APGEGxTvA/viewform?usp=header ุงู„ุตูุฑ ู„ุง ุชู†ุทุจู‚ ูค- ุชู†ุทุจู‚ ุฌุฏุงู‹ ุงู„ ูกุŒูข- ุชู†ุทุจู‚ ู…ุนุธู… ุงู„ูˆู‚ุช

ุงุฎูˆุงู† ุณุงุนุฏูˆุง ุฒู…ู„ุงุฆูƒู… ุจู…ู„ุฆ ุงู„ุงุณุชุจูŠุงู†ุงุชโ™ฅ๏ธ

- ุงู„ุฑุณุงู„ู‡ ุ› ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุงุญู†ุง ุทู„ุงุจ ุตูŠุฏู„ุฉ ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ุนุฏู†ุง ุจุญุซ ูŠู‡ุฏู ุฅู„ู‰ ู…ู‚ุงุฑู†ุฉ ุงู„ุงุซุงุฑ ุงู„ุฌุงู†ุจูŠุฉ ูˆุชุญู…ู„ ุงู„ู…ุฑูŠุถ ู„ู„ู…ูŠุชููˆุฑู…ูŠู† ู…ู‚ุงุจู„ ู…ุซุจุทุงุช DPP4 inhibitors ูŠุง ุฑูŠุช ุชุดุงุฑูƒูˆู†ู‡ ุฑุฆูŠูƒู… ูˆุชู†ุทูˆู†ู‡ ุฌุฒุก ุจุณูŠุท ู…ู† ูˆู‚ุชูƒู… ุชู…ู„ูˆู† ู‡ุฐุง ุงู„ุงุณุชุจูŠุงู† ๐ŸŒธ https://docs.google.com/forms/d/1EdInAEsPRrpWhN590WCoHnS5CqnFaF0mHuUrsxGOoiA/viewform

Dyslipidemia Arrhythmia Thrombosis ุงู„ู…ูˆุงุถูŠุน ุงู„ู‚ุงุฏู…ุฉ ุฅู† ุดุงุก ุงู„ู„ู‡ ูˆุจุนุฏู‡ุง ุงุฐุง ุงูƒูˆ ูˆู‚ุช ุงุดุฑุญ ูƒู… ู…ูˆุถูˆุน ูˆุงุฐุง ู…ุงูƒูˆ ู ุงุนุชุฐุฑ ุนู† ุงูƒู…ุงู„ ุงู„ุฌุฒุก ุงู„ุจุงู‚ูŠ ู„ุงู† ู„ุงุฒู… ุงุจุฏูŠ ุงุดุฑุญ ุงู„ู…ุงุฏุฉ ุงู„ูˆุฒุงุฑูŠุฉ

ุทู„ุงุจ ุงู„ูŠ ุนู†ุฏู‡ ุดุฑุญ ุฒูŠู† ู„ู„ูƒูŠู…ูŠุงุก ุณุฑูŠุฑูŠุฉ ุฏุฒูˆู‡ู† ุจุงู„ุชุนู„ูŠู‚ุงุช

The first-choice vasopressor in septic shock in patient suffer from tachydysarrhmia is: A. Norepinephrine B. Dobutamine C. Epinephrine D. Phenylephrin

From the previous case. What is the MAP: A) 30 B) 40 C) 50 D) 60 E) None of the above

A previously fit 35-year-old man presents to emergency department with septic shock secondary to arm cellulitis. He is cold peripherally and slightly confused. His HR is 125/min NSR, BP 60/30 mmHg, Respiratory rate 25/min. if his weight is 60 kg, his initial management should be:
A)Start IV fluid 1000 mL in 1 hour B)Start IV fluid 2000 mL in 1 hour C)Start Noradrenaline D)Start Dobutamine E)Start Dopamine

ุงุฎูŠุฑุง๐Ÿ™‚โ€โ†•๏ธ

- ุงู„ุฑุณุงู„ู‡ ุ› ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ู†ุดุชุบู„ ุนู„ู‰ ุจุญุซ ุงู„ุชุฎุฑุฌ ุงู„ุนู†ูˆุงู† ุนู† ุงู†ุชุดุงุฑ ูู‚ุฑ ุงู„ุฏู… ุจูŠู† ุทู„ุงุจ ุงู„ุฌุงู…ุนุงุช ู†ุฑุฌูˆ ู…ู†ูƒู… ุงู„ุชูุถู„ ุจุงู„ู…ุดุงุฑูƒุฉ ููŠ ู‡ุฐุง ุงู„ุงุณุชุจูŠุงู† ูˆุดูƒุฑุง https://docs.google.com/forms/d/e/1FAIpQLSdSudGo_7m3_V1oPehUFuDtkXSDAi4RCXviFm_GlclY4GpNkA/viewform?usp=dialog

- ุงู„ุฑุณุงู„ู‡ ุ› ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ู„ุทูุงู‹ ู…ู…ูƒู† ู…ู„ุฆ ุงู„ุงุณุชุจูŠุงู† ุŒ ุฑุงุฆูŠูƒู… ูŠู‡ู…ู†ุง https://docs.google.com/forms/d/e/1FAIpQLSd2Avx91uJHMJpKelXQDLj4j91SyvK1bIBMdfmC30opZAip6w/viewform?usp=header

ู†ุณุฎุฉ ู…ู† SHOCK.pdf.pdf3.98 MB

- ุงู„ุฑุณุงู„ู‡ ุ› ุงู„ุณู„ุงู… ุนู„ูŠูƒู… ุฏูƒุชูˆุฑ ุงู†ูŠ ุทุงู„ุจุฉ ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ุฏูƒุชูˆุฑ ู†ุญุชุงุฌ ู…ุฑุงูƒุฒ ุชุญู„ูŠู„ูŠุฉ ุงูˆ ู…ูƒุงุชุจ ุงู„ุนู„ู…ูŠุฉ ุงุฐุง ุนุฏู‡ู… ุฃุฌู‡ุฒุฉ ูƒูŠู…ูŠุงุก ุชุญู„ูŠู„ูŠุฉ ู†ุฑูŠุฏ ู„ุจุญุซ ุชุฎุฑุฌู†ู‡ ุงู„ุดุบู„ ุงู„ุนู…ู„ูŠ ู…ุงู„ุชู†ู‡ ุงู†ูˆ ู†ุญู„ู„ ุฌูŠู„ุงุชูŠู† ูƒุจุณูˆู„ ุจุฃุฌู‡ุฒุฉ ุชุญู„ูŠู„ูŠุฉ ุงู„ูŠ ุฑุงุญ ุงุฏุฒู‡ ุงู„ุฌ ู‡ุณู‡ ุญุชู‰ ู†ุนุฑู ู‡ุฐุง ุฌูŠู„ุงุชูŠู† ุญูŠูˆุงู†ูŠ ุงูˆ ู†ุจุงุชูŠ 1. ุงู„ุชุญู„ูŠู„ ุงู„ู†ูˆุนูŠ ู„ู„ู…ูƒูˆู†ุงุช ุงู„ูƒูŠู…ูŠุงุฆูŠุฉ ุฃ. ุงุฎุชุจุงุฑ ุงู„ุฐูˆุจุงู† ุจ. ุงุฎุชุจุงุฑ ุงู„ุจุฑูˆุชูŠู† (ุงุฎุชุจุงุฑ ุงู„ุจูŠูˆุฑูŠุช - Biuret Test) ุฌ. ุงุฎุชุจุงุฑ ุงู„ููŠู†ูˆู„ูุซุงู„ูŠู† 2. ุงู„ุชุญู„ูŠู„ ุงู„ุทูŠููŠ (Spectroscopy Analysis) ุฃ. ุชุญู„ูŠู„ FTIR (ุชุญู„ูŠู„ ุทูŠู ุงู„ุฃุดุนุฉ ุชุญุช ุงู„ุญู…ุฑุงุก) ุจ. ุชุญู„ูŠู„ ุงู„ุฃุดุนุฉ ููˆู‚ ุงู„ุจู†ูุณุฌูŠุฉ UV-Vis 3. ุงู„ุชุญู„ูŠู„ ุงู„ุญุฑุงุฑูŠ (TGA ูˆ DSC) 4. ุงู„ุชุญู„ูŠู„ ุงู„ูƒุฑูˆู…ุงุชูˆุฌุฑุงููŠ (HPLC ูˆ GC-MS) 5. ุงู„ูุญุต ุงู„ู…ุฌู‡ุฑูŠ ุงู„ุฅู„ูƒุชุฑูˆู†ูŠ (SEM-EDX) ุงูˆ ุบูŠุฑู‡ู† ู…ุซู„ุง million test Sudan test